Natera, Inc. Common Stock (NTRA) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT)...
Natera, Inc. Common Stock's revenue increased 35.9% year over year, from $1.70B to $2.31B.
Net income decreased 9.3% over the same period, from $-190.4M to $-208.2M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 962% in total.
Total debt remained relatively stable at $80.3M.
The debt-to-equity ratio stands at 0.05, indicating a conservative leverage profile.
Operating cash flow grew 58.7% to $215.3M.
Natera, Inc. Common Stock maintains a negative net profit margin of -9.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $413.4M+12.4% | $-37.5M | $243.2M | $-43.9M | $4.0M | $1.52B | $80.4M | $836.5M |
| Q3 FY2024 | $439.8M+6.4% | $-31.6M | $271.7M | $-39.3M | $51.8M | $1.59B | $80.5M | $878.5M |
| Q4 FY2024 | $476.1M+8.3% | $-53.7M | $299.6M | $-64.7M | $52.9M | $1.66B | $80.4M | $1.20B |
| Q1 FY2025 | $501.8M+5.4% | $-66.9M | $316.8M | $-79.2M | $44.5M | $1.73B | $80.3M | $1.24B |
| Q2 FY2025 | $546.6M+8.9% | $-101.0M | $346.6M | $-110.4M | $37.6M | $1.76B | $80.3M | $1.25B |
| Q3 FY2025 | $592.2M+8.3% | $-87.5M | $384.4M | $-97.6M | $59.4M | $1.82B | $80.3M | $1.25B |
| Q4 FY2025 | $665.5M+12.4% | $47.2M | $445.4M | $-22.8M | $73.9M | $2.40B | $80.3M | $1.71B |
| Q1 FY2026 | $696.6M+4.7% | $-85.1M | $450.8M | $-93.5M | $40.2M | $2.61B | $80.3M | $1.77B |
Balance Sheet Summary (Latest Period)
Natera, Inc. Common Stock (NTRA) Financial Statements & Revenue History
Natera, Inc. Common Stock (NTRA) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry trading at $409.00 with a market capitalization of $59. This page provides 41 historical financial statements for Natera, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Natera, Inc. Common Stock reported revenue of $2.3 billion, representing 35.9% year-over-year growth. The net profit margin of -9.0% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.05 shows conservative leverage.
NTRA Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Natera, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether NTRA is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track NTRA's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Natera, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of NTRA's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use NTRA Financial Data
Investors use Natera, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare NTRA's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how NTRA's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View NTRA's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Natera, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.NTRA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.